ClinicalTrials.gg
Active, not recruitingNCT04181827CARTITUDE-4Updated Nov 3, 2026Results posted

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

A Phase 3 interventional study of Cilta-cel and Pomalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 88 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
419
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ciltacabtagene autoleucel in Multiple Myeloma — 3 open to participants now, 7 under way, 1 of them phase 3. ciltacabtagene autoleucel · Multiple Myeloma.

Enrollment
Largest of 10
419 · median 105
Started
2020
the only one that year
Phase 3
Only one
of the 10
Registered
4th of 10
by date
Lead sponsor
5 of 10
Janssen Research & Development, LLC

Among the 10 studies testing ciltacabtagene autoleucel in Multiple Myeloma, this one has the largest enrollment, is the only one that started in 2020, is the only one in phase 3, and was the 4th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

3 of the 10 studies testing ciltacabtagene autoleucel in Multiple Myeloma are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ciltacabtagene autoleucel

ciltacabtagene autoleucel: first FDA approval 2022 (Carvykti), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ciltacabtagene autoleucel in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at screening as defined by any of the following: (a) Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 0.5 gram per deciliter (g/dL) or urine M-protein level >=200 milligram (mg)/24 hours; or (b) Light chain multiple myeloma without measurable M-protein in the serum or the urine: Serum free light chain >=10 mg/dL and abnormal serum free light chain ratio
  • Have received 1 to 3 including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD)
  • Have documented evidence of PD by International Myeloma Working Group (IMWG) criteria based on investigator's determination on or within 6 months of their last regimen
  • Be to lenalidomide per IMWG consensus guidelines (failure to achieve minimal response or progression on or within 60 days of completing lenalidomide therapy). Progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion. For participants with more than 1 prior line of therapy, there is no requirement to be lenalidomide refractory to the most recent line of prior therapy. However, participants must be refractory to lenalidomide in at least one prior line
  • Have clinical laboratory values meeting the following criteria during the Screening Phase (re testing is allowed but the below criteria must be met in the latest test prior to randomization):

    1. >=8 gram per deciliter (g/dL) (without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted);
    2. (ANC) >=1 * 10\^9 per liter (L) (without recombinant human granulocyte colony-stimulating factor [G-CSF] within 7 days and without pegylated G-CSF within 14 days of the laboratory test);
    3. count >=75 * 10\^9/L (without prior platelet transfusion within 7 days before the laboratory test) in participants in whom less than (\<) 50 percent (%) of bone marrow nucleated cells are plasma cells; platelet count >=50 * 10\^9/L (without prior platelet transfusion within 7 days before the laboratory test) in participants in whom >=50% of bone marrow nucleated cells are plasma cells;
    4. Lymphocyte count >=0.3 * 10\^9/L;
    5. (AST) less than or equal to (\<=)3 * (ULN);
    6. Alanine aminotransferase (ALT) \<=3 * ULN;
    7. Total \<=2.0 * ULN; except in participants with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin \<=1.5 * ULN is required);
    8. Estimated >=40 milliliter per minute (mL/min) per 1.73 meter square (m\^2) (to be calculated using the Modification of Diet in Renal Disease [MDRD] formula)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy directed at any target
  • Any previous therapy that is targeted to B-cell maturation antigen (BCMA)
  • Ongoing toxicity from previous anticancer therapy that has not resolved to baseline levels or to Grade 1 or less; except for alopecia
  • Participants with Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral neuropathy will not be permitted to receive pomalidomide, bortezomib, and dexamethasone (PVd) as standard therapy or bridging therapy; however, participants may receive daratumumab, pomalidomide, and dexamethasone (DPd) as standard therapy or bridging therapy
  • Received a cumulative dose of equivalent to >=70 mg of prednisone within the 7 days prior to randomization
  • Monoclonal antibody treatment within 21 days
  • Cytotoxic therapy within 14 days
  • Proteasome inhibitor therapy within 14 days
  • Immunomodulatory drug (IMiD) therapy within 7 days
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
419 participants (actual)

Study arms

  • Experimental
    Arm A: PVd or DPd (Standard Therapy)

    Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m\^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.

    Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone · Drug: Daratumumab

  • Experimental
    Arm B: (Ciltacabtagene Autoleucel [Cilta-cel])

    Participants will receive at least one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of cilta-cel along with conditioning regimen (cyclophosphamide 300 milligram \[mg\]/m\^2 intravenous \[IV\] and fludarabine 30 mg/m\^2 IV daily, for 3 days), and cilta-cel infusion 0.75 \* 10\^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).

    Drug: Cilta-cel

Interventions

  • Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).

  • Pomalidomide 4 mg will be administered orally.

  • Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).

  • Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.

  • Daratumumab 1800 mg will be administered SC.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS: defined as time from date of randomization to date of first documented progressed disease (PD) as per International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurred first. PD: increase of 25% from lowest response value: serum and urine M-component (absolute increase must be \>=0.5 grams per deciliter \[g/dL\] and \>=200 milligrams \[mg\] per 24 hours, respectively); only in participants without measurable serum and urine M-protein levels, difference between involved and uninvolved free light chain (FLC) levels (absolute increase of \>10 mg/dL); only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell (PC)% (absolute increase of \>=10%), appearance of new lesion; definite development of new bone lesions or definite increase in size of existing bone lesions, \>=50% increase in circulating PCs (minimum of 200 cells per microliter \[uL\]) if this was only measure of disease.

    Time frame: From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)

Secondary outcomes

  1. Percentage of Participants Who Achieved Complete Response (CR) or Stringent Complete Response (sCR)

    Time frame: From randomization (Day 1) up to 7 years

  2. Percentage of Participants Who Achieved Overall Minimal Residual Disease (MRD) Negative Status (at 10^-5)

    Time frame: From randomization (Day 1) up to 7 years

  3. Percentage of Participants Who Were in CR or sCR and Achieved MRD-negative Status at 12 Months +/-3 Months

    Time frame: From randomization (Day 1) up to 12 months +/- 3 months

  4. Percentage of Participants Who Achieved Sustained MRD-negative Status

    Time frame: From randomization (Day 1) up to 7 years

  5. Overall Survival (OS)

    Time frame: From randomization (Day 1) up to 7 years

  6. Time to Worsening of Symptoms Using the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Total Symptom Score

    Time frame: From randomization (Day 1) up to 7 years

  7. Overall Response Rate (ORR)

    Time frame: From randomization (Day 1) up to 7 years

  8. Progression Free Survival on Next-line Therapy (PFS2)

    Time frame: From randomization (Day 1) up to 7 years

  9. Number of Participants With Treatment-emergent Adverse Events (AEs)

    Time frame: From Cycle 1 Day 1 up to 7 years

  10. Number of Participants With Treatment-emergent Adverse Events (AEs) by Severity

    Time frame: From Cycle 1 Day 1 up to 7 years

  11. Change From Baseline in Systemic Cytokine Concentrations on Participants Who Received Cilta-cel as Study Treatment (Arm B)

    Time frame: From baseline (Cycle 1 Day 1) up to 7 years

  12. Change From Baseline in Levels of CAR-T Cell Activation Markers on Participants Who Received Cilta-cel as Study Treatment (Arm B)

    Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

  13. Change From Baseline in Levels of JNJ-68284528 T Cell Expansion (Proliferation), and Persistence on Participants Who Received Cilta-cel as Study Treatment (Arm B)

    Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

  14. Number of Participants With Anti-JNJ-68284528 Antibodies on Participants Who Received Cilta-cel as Study Treatment (Arm B)

    Time frame: From Cycle 1 Day 1 up to 7 years

  15. Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 Item (EORTC-QLQ-C30) Scale Score

    Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

  16. Change From Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Sore

    Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

  17. Change From Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Scale Score

    Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

  18. Change From Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score

    Time frame: From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

  19. Number of Participants in Health-Related Quality of Life as Assessed by The Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item

    Time frame: From randomization (Day 1) up to 7 years

07

Results

Posted May 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm A: Standard Therapy: PVd or DPdArm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])
Started211208
Treated (safety analysis set)208208
Completed00
Not completed211208
Withdrew: Ongoing124157
Withdrew: Death8250
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject50

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS: defined as time from date of randomization to date of first documented progressed disease (PD) as per International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurred first. PD: increase of 25% from lowest response value: serum and urine M-component (absolute increase must be \>=0.5 grams per deciliter \[g/dL\] and \>=200 milligrams \[mg\] per 24 hours, respectively); only in participants without measurable serum and urine M-protein levels, difference between involved and uninvolved free light chain (FLC) levels (absolute increase of \>10 mg/dL); only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell (PC)% (absolute increase of \>=10%), appearance of new lesion; definite development of new bone lesions or definite increase in size of existing bone lesions, \>=50% increase in circulating PCs (minimum of 200 cells per microliter \[uL\]) if this was only measure of disease.

Time frame:
From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsArm A: Standard Therapy: PVd or DPdArm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])
Progression Free Survival (PFS)11.79 (9.66 to 14.00)NA (34.50 to NA)
SecondaryPercentage of Participants Who Achieved Complete Response (CR) or Stringent Complete Response (sCR)
Time frame:
From randomization (Day 1) up to 7 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved Overall Minimal Residual Disease (MRD) Negative Status (at 10^-5)
Time frame:
From randomization (Day 1) up to 7 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Were in CR or sCR and Achieved MRD-negative Status at 12 Months +/-3 Months
Time frame:
From randomization (Day 1) up to 12 months +/- 3 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved Sustained MRD-negative Status
Time frame:
From randomization (Day 1) up to 7 years

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)
Time frame:
From randomization (Day 1) up to 7 years

Results for this outcome have not been posted.

SecondaryTime to Worsening of Symptoms Using the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Total Symptom Score
Time frame:
From randomization (Day 1) up to 7 years

Results for this outcome have not been posted.

SecondaryOverall Response Rate (ORR)
Time frame:
From randomization (Day 1) up to 7 years

Results for this outcome have not been posted.

SecondaryProgression Free Survival on Next-line Therapy (PFS2)
Time frame:
From randomization (Day 1) up to 7 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (AEs)
Time frame:
From Cycle 1 Day 1 up to 7 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (AEs) by Severity
Time frame:
From Cycle 1 Day 1 up to 7 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Systemic Cytokine Concentrations on Participants Who Received Cilta-cel as Study Treatment (Arm B)
Time frame:
From baseline (Cycle 1 Day 1) up to 7 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Levels of CAR-T Cell Activation Markers on Participants Who Received Cilta-cel as Study Treatment (Arm B)
Time frame:
From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Levels of JNJ-68284528 T Cell Expansion (Proliferation), and Persistence on Participants Who Received Cilta-cel as Study Treatment (Arm B)
Time frame:
From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti-JNJ-68284528 Antibodies on Participants Who Received Cilta-cel as Study Treatment (Arm B)
Time frame:
From Cycle 1 Day 1 up to 7 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 Item (EORTC-QLQ-C30) Scale Score
Time frame:
From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Sore
Time frame:
From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Scale Score
Time frame:
From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score
Time frame:
From baseline (Cycle 1 Day 1) up to 7 years (each cycle of 28 days)

Results for this outcome have not been posted.

SecondaryNumber of Participants in Health-Related Quality of Life as Assessed by The Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item
Time frame:
From randomization (Day 1) up to 7 years

Results for this outcome have not been posted.

Adverse events

Collected over All-cause mortality: From randomization (Day 1) up to 3.9 years; SAEs/Other AEs: Arm A: From Cycle 1 Day 1 up to 45 months; Arm B: From Cycle 1 Day 1 up to 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Standard Therapy: PVd or DPd83/211 (39.3%)98/208 (47.1%)207/208 (99.5%)
Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])50/208 (24%)98/208 (47.1%)208/208 (100%)
Most frequent serious events
Showing 10 of 164
Most frequent serious events
EventArm A: Standard Therapy: PVd or DPdArm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])
PneumoniaInfections and infestations14/2088/208
Covid-19 PneumoniaInfections and infestations12/20812/208
Facial ParalysisNervous system disorders1/2089/208
Cytokine Release SyndromeImmune system disorders1/2087/208
Covid-19Infections and infestations7/2086/208
Febrile NeutropeniaBlood and lymphatic system disorders6/2085/208
DiarrhoeaGastrointestinal disorders0/2085/208
PyrexiaGeneral disorders5/2084/208
Pneumocystis Jirovecii PneumoniaInfections and infestations5/2081/208
Upper Respiratory Tract InfectionInfections and infestations5/2084/208
Most frequent other events
Showing 10 of 61
Most frequent other events
EventArm A: Standard Therapy: PVd or DPdArm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])
NeutropeniaBlood and lymphatic system disorders178/208187/208
Cytokine Release SyndromeImmune system disorders0/208129/208
ThrombocytopeniaBlood and lymphatic system disorders67/208113/208
AnaemiaBlood and lymphatic system disorders57/208110/208
NauseaGastrointestinal disorders43/208101/208
HypogammaglobulinaemiaImmune system disorders18/20894/208
FatigueGeneral disorders70/20860/208
DiarrhoeaGastrointestinal disorders65/20869/208
Covid-19Infections and infestations61/20816/208
HeadacheNervous system disorders27/20855/208

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Standard Therapy: PVd or DPdArm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])Total
Mean60.4 ± 9.0959.7 ± 10.0960.1 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Standard Therapy: PVd or DPdArm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])Total
Female8792179
Male124116240
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Standard Therapy: PVd or DPdArm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])Total
Hispanic or Latino101828
Not Hispanic or Latino165152317
Unknown or Not Reported363874
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Standard Therapy: PVd or DPdArm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])Total
American Indian or Alaska Native112
Asian201636
Native Hawaiian or Other Pacific Islander000
Black or African American7613
White157157314
More than one race000
Unknown or Not Reported262854
08

Study locations

88 sites
09

References and documents

Publications

  • Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Shune L, Isufi I, Harrison SJ, Shah UA, De Champlain A, Katz EG, Gries KS, Schecter JM, Lendvai N, Slaughter A, Lonardi C, Deraedt W, Costa Filho O, Patel N, Florendo E, Ho KF, Karlin L, Weisel K. Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. J Patient Rep Outcomes. 2026 Mar 13;10(1):64. doi: 10.1186/s41687-026-01034-z. PubMed 41824255 ↗
  • Lopez-Munoz N, Bar N, Diels J, van Sanden S, Mendes J, Lee S, Hernando T, Lendvai N, Patel N, Ishida T, Er J, Harrison SJ. Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. Adv Ther. 2026 Mar;43(3):1327-1340. doi: 10.1007/s12325-025-03479-y. Epub 2026 Feb 2. PubMed 41627370 ↗
  • Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martinez-Lopez J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2026 Feb;27(2):254-268. doi: 10.1016/S1470-2045(25)00653-9. Epub 2026 Jan 7. PubMed 41519141 ↗
  • Touzeau C, Lipe B, Khan AM, Dhakal B, Nair S, He J, Mendes J, Lee S, Lonardi C, Slaughter A, Lendvai N, Schecter JM, Chen D, Zhao M, Yeh TM, Leleu X, Puig N, Dytfeld D, Zamagni E, Weisel K, Karlin L, Delforge M, Corradini P, Mina R, Roeloffzen W, Sidana S. Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma. Adv Ther. 2025 Oct;42(10):5023-5041. doi: 10.1007/s12325-025-03308-2. Epub 2025 Aug 6. PubMed 40768190 ↗
  • Fonseca R, Diels J, Ghilotti F, Mendes J, Van Hoorenbeeck S, Lee S, Schecter JM, Lendvai N, Patel N, Triguero A, Alsdorf W, van de Donk NWCJ, Ursi M. Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting. Adv Ther. 2025 Sep;42(9):4418-4431. doi: 10.1007/s12325-025-03278-5. Epub 2025 Jul 4. PubMed 40613875 ↗
  • Harrison SJ, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, Rahman M, Le Bris Y, Er J, Eugene-Lamer J, Haynes NM, Li J, Abbott RC, Bodet-Milin C, Moreau A, Letouze E, Lendvai N, Schecter JM, Deraedt W, Banerjee A, Lengil T, Vogel M, Foulk B, Zhao H, Smirnov D, Slaughter A, Lonardi C, Lee E, Marquez L, Sankari A, Plaks V, Filho JOC, Patel N, Geng D, Gastinne T, Kelly H, Tiong IS, Eveillard M, Chevallier P, Lade S, Moreau P, Grimmond S, Oliaro J, Tessoulin B, Blombery P. CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma. N Engl J Med. 2025 Feb 13;392(7):677-685. doi: 10.1056/NEJMoa2309728. PubMed 39938094 ↗
  • Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, Shune L, Isufi I, Harrison SJ, Shah UA, Schecter JM, Vogel M, Lendvai N, Gries KS, Katz EG, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho OC, Patel N, Florendo E, Karlin L, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X. PubMed 39756844 ↗
  • Hansen DK, Lu X, Puglianini OC, Sorensen S, Usmani SZ, Zhang E, Huo S, Zhang Y, Qureshi ZP, Jagannath S. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4. Front Immunol. 2024 Aug 21;15:1408892. doi: 10.3389/fimmu.2024.1408892. eCollection 2024. PubMed 39234256 ↗
  • San-Miguel J, Dhakal B, Patel N, Schecter JM, Lendvai N, Einsele H. Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. Future Oncol. 2024;20(33):2509-2520. doi: 10.1080/14796694.2024.2376973. Epub 2024 Aug 7. PubMed 39110421 ↗
  • San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernandez de Larrea C, Martinez-Lopez J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5. PubMed 37272512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2024, 46 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 46 months is close to that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2019
First posted
Dec 2, 2019
StartActual
Jun 12, 2020
Primary completionActual
May 1, 2024
CompletionEst.
Mar 31, 2027
Results first posted
May 20, 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04181827
Responsible party
Sponsor
First posted
Dec 2, 2019
Start date
Jun 12, 2020
Primary completion
May 1, 2024
Completion
Mar 31, 2027 (estimated)
Results posted
May 20, 2025
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ciltacabtagene autoleucel · Pomalidomide · Bortezomib · Dexamethasone · Daratumumab

Start the discussion